Answers are grounded in this paper and cite their sources.
Case report reveals pan drug-resistant Acinetobacter baumannii in a repatriated patient, highlighting the urgent need for strict screening and preemptive isolation.
Sir, In December 2013, a carbapenem-resistant Acinetobacter baumannii was recovered from routine skin and rectum swabs from a patient during admission screening. The patient had been on a repatriation transport to Australia after previous hospitalization in Greece due to Waterhouse–Friderichsen syndrome as a result of severe meningococcal septicaemia. At the stop-over in Germany he presented with a decreased level of consciousness, multiple decubitus ulcers (grade IV) and reduced general condition and was admitted to the Internal Medicine Intensive Care Unit at the Hospital of the Johann Wolfgang von Goethe University in Frankfurt. Infection parameters were elevated, although a definite infection focus could not be established. Empirical anti-infective therapy with colistin, meropenem, linezolid, fosfomycin and caspofungin was initiated. The patient recovered after 1 week and could be transferred. Susceptibility testing of the A. baumannii isolate using the Etest method revealed non-susceptibility to all antibiotic groups where breakpoints have been defined for Acinetobacter spp. by either EUCAST or CLSI (penicillins/β-lactamase inhibitors, extended-spectrum cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, tetracyclines, folate pathway inhibitors and polymyxins), including colistin, with an MIC of 128 mg/L (Table 1).1,2 The A. baumannii isolate was thus categorized as pan drug-resistant (PDR) in accordance with the guidelines defined by the international expert committee of the European Centre for Disease Prevention and Control (ECDC) and CDC.3 First reports of PDR A. baumannii emerged in 2001 and a nosocomial outbreak with PDR A. baumannii in 2002 was reported from Spain.4,5 However, in many other studies the term PDR was used inappropriately since important antibiotics such as colistin and ampicillin/sulbactam were not tested.3,6 Notably, the isolate remained intermediately susceptible to minocycline with an MIC of 8 mg/L. Interestingly, previous studies reported in vitro activity of minocycline, an old, rarely used tetracycline derivative, against >70% of multidrug-resistant (MDR) A. baumannii.7 Antibiotic susceptibility of A. baumannii isolated from a colonized patient admitted at the Hospital of the Johann Wolfgang von Goethe University in Frankfurt, Germany, in December 2013 R, resistant; I, intermediately susceptible. aMICs were interpreted according to breakpoints for Acinetobacter spp. set by EUCAST and CLSI.1,2 MICs of tigecycline, chloramphenicol and fosfomycin were interpreted according to breakpoints for Enterobacteriaceae set by EUCAST. bβ-Lactamase inhibitors sulbactam, tazobactam and clavulanic acid were used at a fixed concentration of 4, 4 and 2 mg/L, respectively, as recommended by EUCAST. Antibiotic susceptibility of A. baumannii isolated from a colonized patient admitted at the Hospital of the Johann Wolfgang von Goethe University in Frankfurt, Germany, in December 2013 R, resistant; I, intermediately susceptible. aMICs were interpreted according to breakpoints for Acinetobacter spp. set by EUCAST and CLSI.1,2 MICs of tigecycline, chloramphenicol and fosfomycin were interpreted according to breakpoints for Enterobacteriaceae set by EUCAST. bβ-Lactamase inhibitors sulbactam, tazobactam and clavulanic acid were used at a fixed concentration of 4, 4 and 2 mg/L, respectively, as recommended by EUCAST. Detection of carbapenemases by PCR for acquired β-lactamase (bla) genes encoding VIM, IMP, NDM, KPC and OXA-23, -40, -48, -58, -143 and -235 using whole-cell DNA and subsequent sequencing revealed the presence of the carbapenemase blaOXA-23.8 PFGE and subsequent blaOXA-23 detection by Southern hybridization suggested a chromosomal location for the OXA-23 gene. A 3.5 kb sequence obtained by primer walking revealed that it was located in transposon Tn2008 (GenBank accession number HQ008358) and embedded in the chromosomal lysE gene (locus tag ADU58354). Molecular strain typing was performed by semi-automated, repetitive sequence-based PCR (rep-PCR) using the DiversiLab platform (bioMérieux, Nürtingen, Germany). Our isolate grouped with the international clone (IC) 2, also known as European clone 2.7 Furthermore, subtyping of the chromosomally located intrinsic OXA-51-like bla gene identified blaOXA-66, which is also associated with IC2. IC2 accounts for ∼50% of all isolates worldwide and can therefore be considered as the most successful and widespread clonal lineage of A. baumannii.7,9 There are no German national surveys of A. baumannii carbapenem resistance rates. However, in smaller surveys it has been shown that carbapenem resistance, although not prevalent, is most often associated with IC2 isolates.10 Furthermore, in contrast to the PDR isolate, carbapenem-resistant isolates belonging to IC2 are usually susceptible to minocycline, tigecycline and polymyxins.7,10 This is the first report of a PDR A. baumannii isolate in Germany. Since PDR Gram-negatives will further disseminate and no treatment options are left, rigorous screening and pre-emptive isolation of patients with a history of medical treatment in a country where MDR Gram-negatives are endemic seems indispensable. This work was supported by the Frankfurt Initiative for Microbial Sciences (FIMS). S. G. was supported by the programme ‘Frankfurter Forschungsförderung (FFF)’ by the Faculty of Medicine of the Johann Wolfgang von Goethe University, Frankfurt. None to declare. We thank Rebecca A. Kaufmann and Julian Sommer for excellent technical assistance.
No takes yet. Share an insight, caveat, or question.
Göttig et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: